Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Celltrion (068270) Amends Share Retirement Details, Confirming 488,977 Common Shares for Retirement and Updating Total Value

Posted on May 6, 2026July 14, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) Amends Share Retirement Details, Confirming 488,977 Common Shares for Retirement and Updating Total Value

Source: Financial Supervisory Service Data Analysis, Retrieval and Transfer System (DART) / 2026-05-06

Disclosure Type: Decision on Share Retirement

💡 3-Second Summary

Following the completion of its treasury share acquisition, Celltrion has amended its share retirement details, updating the number of common shares to be retired from 488,983 to 488,977 and adjusting the estimated retirement value to approximately KRW 100.07B.

📊 1. [Key Disclosure Details & Major Figures Summary]

  • Purpose of Retirement: Price stabilization and enhancement of shareholder value
  • Type and Number of Shares to be Retired (Amended):
    • Common Shares: (Before) 488,983 shares ➡️ (After) 488,977 shares (A decrease of 6 shares)
  • Estimated Retirement Value (Amended):
    • Amount: (Before) KRW 100,000,033,000 ➡️ (After) KRW 100,067,873,770 (An increase of KRW 67,840,770)
    • Note: The estimated retirement value is based on the accounting book value of the treasury shares acquired within the limits of dividendable profits as of the disclosure date.
  • Scheduled Retirement Date: May 21, 2026
  • Acquisition Method and Period:
    • Method: On-market acquisition
    • Acquisition Period: April 23, 2026 ~ May 6, 2026 (Based on transaction execution dates)
  • Financial Characteristics of Retirement: This retirement is conducted with treasury shares acquired within the scope of dividendable profits. While the total number of outstanding common shares (currently 222,122,341 shares) will decrease, there will be no reduction in the company’s registered capital stock.

📈 2. [Expert Perspective: What This Means for Investors]

  • Finalization of Share Count and Value Post-Acquisition: This amendment reports the adjusted final figures for the share retirement following the completion of the treasury share acquisition. Compared to the pre-amended figures, the number of shares decreased by 6 shares, and the estimated value increased by approximately KRW 67.8M. The official disclosure does not state specific reasons for these changes in figures.
  • Reduction in Outstanding Shares with No Capital Decrease: The retirement of treasury shares will physically decrease the total outstanding shares while keeping the registered capital stock unchanged. Investors should focus on the objective fact that the overall volume of outstanding shares will decrease from 222,122,341 shares by the specified amount once the process is complete.
  • Operational Notes: The scheduled retirement date is set for May 21, 2026, though this date may be subject to change during discussions with relevant regulatory bodies. This filing also replaces the disclosure on the disposal of treasury shares as the acquired shares are set to be directly retired.

📝 Editor’s Comment (by K-STOCK Editor)

This is an administrative amendment outlining the finalized share count and estimated value of the retirement following the completion of treasury share acquisitions. As the official document does not explain the operational or accounting factors behind the slight adjustments in quantity and value, readers should refrain from making speculative inferences. The primary point of interest for investors is simply verifying whether the retirement of the 488,977 common shares proceeds on the scheduled date of May 21, 2026, and noting the corresponding physical decrease in outstanding shares.

📢 Disclaimer & Sources

Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Title] [Disclosure] Samsung Electro-Mechanics Pref (009150) Designated as ‘Investment Caution Stock’ as Foreign Accounts Dominate 53.9% of Buys Amid 77% Surge
Next Post: [Disclosure] Celltrion (068270) Decides to Retire 488,983 Common Shares Valued at Approx. KRW 100B for Price Stabilization and Boosting Shareholder Value

Related Posts

[Disclosure] Celltrion (068270) Announces Expiration of Part 1 Approval for ‘Remsima SC’ Pediatric Ulcerative Colitis Phase 3 Trial in Europe Due to Strategic Shift Bio & Healthcare
[Disclosure] Celltrion 068270 Signs KRW 712.5B Co-Development and License Agreement with Mustbio for Tri-specific Fusion Protein Therapeutics Disclosures
[Disclosure] Samsung Biologics (207940) Signs KRW 211.5B CMO Main Contract with Kiniksa Pharmaceuticals Disclosures
[Disclosure] Samsung Biologics (207940) Stock Futures and Options to Be Suspended from Trading Starting October 30 Due to Underlying Asset Halt Disclosures
[Disclosure] Celltrion (068270) Announces Executive Leadership Restructuring, Transitioning to Co-Representative System Under ‘Woo-Sung Kee and Jin-Seok Seo’ Following Hyoung-Ki Kim’s Resignation Disclosures
[Disclosure] Samsung Electronics (005930) Confirms KRW 287.5B Treasury Share Disposal… Delivering Massive Stock-Based Rewards to 123K Employees Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Celltrion (068270) Submits Application to Modify Phase 3 Clinical Trial Plan for ‘CT-P44’ (Darzalex Biosimilar) in EuropeJuly 14, 2026
  • [Disclosure] Hanmi Semiconductor (042700) Reports Q2 2026 Operating Profit of KRW 130.3B… A Explosive 1,441.4% QoQ SurgeJuly 14, 2026
  • [Disclosure] SK Square (402340) Discloses Subsidiary SK Hynix’s Successful ADR Listing on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] SK Hynix (000660) Completes Listing of ADRs (American Depositary Receipts) on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] Samsung Electronics (005930) to Dispose of KRW 322.8B Worth of Treasury Shares for Executive BonusesJuly 13, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme